Elan reports third quarter profit after exceptional gain of $107.7m
Oct 21st, 2009 | By Finfacts Ireland Business & Finance Portal | Category: News worldwide
Elan, the Irish listed drugs company, today reported a net profit of $52.3m for the third quarter of this year, compared with a loss of $83.5m loss in the same period last year - - boosted by an exceptional gain of $107.7m from the acquisition by US healthcare giant Johnson & Johnson of part of Elan's research on the treatment of Alzheimer's disease.